Methylaminolaevulinic acid photodynamic therapy in the treatment of erythroplasia of Queyrat

Dermatology. 2011;223(1):52-6. doi: 10.1159/000330328. Epub 2011 Aug 18.

Abstract

Background: Erythroplasia of Queyrat (EQ) is an intra-epithelial carcinoma of the penis. Progression to invasive carcinoma may occur. Its cause is unknown but some evidence suggests infection with human papillomavirus in the pathogenesis of EQ; however, recent data do not confirm this. Therapy is difficult and associated with important recurrence rates. Photodynamic therapy (PDT) employs a photosensitizer excited by visible light. The resulting photodynamic reaction selectively destroys atypical cells. Only few reports exist on the use of topical PDT in the treatment of EQ.

Objective: We report 11 cases of EQ treated by topical methylaminolaevulinic acid (MAL) PDT.

Results: Out of 11 male patients with EQ treated by topical MAL-PDT, 3 achieved complete remission sustained for 24 and 51 months and 4 a partial remission sustained for 2-45 months with a follow-up period of 4-45 months (1 patient lost to follow-up); surprisingly, 2 of the 4 patients with partial remission presented a complete remission after 20 and 45 months of follow-up, respectively, without further therapy. Four patients showed progression of the disease.

Conclusion: Whereas topical MAL-PDT offers the advantages of tumour specificity, preservation of function and a good cosmetic result, side effects may cause treatment discontinuation in some cases. Treatment of EQ with PDT may represent a valuable option in selected cases, but our data do not allow considering it as a first-line therapeutic option.

MeSH terms

  • Administration, Topical
  • Aged
  • Aged, 80 and over
  • Aminolevulinic Acid / therapeutic use*
  • Erythroplasia / drug therapy*
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Penile Neoplasms / drug therapy*
  • Photochemotherapy / methods*
  • Photosensitizing Agents / therapeutic use*
  • Treatment Outcome

Substances

  • Photosensitizing Agents
  • Aminolevulinic Acid